VivoSeq
Oncology

Anatomic Stage III Breast Cancer AJCC V8

9

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Anatomic Stage III Breast Cancer AJCC v8 is an early-stage landscape with 9 programs across 6 companies. The most active players are Merck & Co., Taiho Oncology, Inc., Teva.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

0/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1Taiho Oncology, Inc. logo

Taiho Oncology, Inc.

1 program

Phase 1Teva logo

Teva

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 2Sanofi logo

Sanofi

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

9programs
Small molecule556%
Monoclonal antibody111%
Antibody–drug conjugate111%
Protein / enzyme111%
Vaccine111%

Modality classified for 100% of 9 pipeline programs.

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Suspended1 · 25%

Clinical Trials

Trial Activity

Phase 1b Study of Pidnarulex and Trastuzumab Deruxtecan in Patients With HER2 Expressing Solid Tumors
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT07137416·36 enrolled
Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer
Suspended·National Cancer Institute (NCI)·Phase 1·NCT05673200·32 enrolled
A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)
Recruiting·MMayo Clinic·Preclinical·NCT05269381·132 enrolled
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT04550494·36 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)